CynosBio

CynosBio is a South Korean biotechnology company specializing in the development of next-generation exosome-based therapeutics and advanced drug delivery systems. The company leverages its proprietary Cynos-Exo platform to engineer exosomes for the targeted delivery of therapeutic payloads, including proteins and nucleic acids. Their research primarily focuses on addressing unmet needs in inflammatory conditions, oncology, and regenerative medicine, with lead programs targeting atopic dermatitis and inflammatory bowel disease. By utilizing the natural communication properties of exosomes, CynosBio aims to enhance the efficacy and safety of biological treatments while overcoming manufacturing challenges. The company is currently in the pre-clinical stage, focusing on high-purity isolation and scalable production of engineered extracellular vesicles.